Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer

NCT01666977 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT01666977
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01666977 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor
Amgen
Phase
Phase 1/2
Overall status
Completed
Start date
August 31, 2012
Completion date
November 30, 2015
Enrollment
36 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer